PCSK9 inhibitors in combination with statins and ezetimibe are recommended for patients with established ASCVD and plasma LDL-C levels ≥70 mg/dL [7, 58, 59, 66] [+, I, A]. The gene discussed is PCSK9; the disease is atherosclerosis.